MoonLake Immunotherapeutics raises additional $30M from underwriters' overallotment exercise

MoonLake Immunotherapeutics

Underwriters exercised in full their option to purchase 1,500,000 additional ordinary shares.
Gross proceeds of $30.0 million from the sale of the option shares, before underwriting discounts.
Closing of the option share issuance occurred on July 14, 2026.
The option was part of a previously announced public offering of ordinary shares and pre-funded warrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.